

CLASSIFICATION: DUAL GIP/GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~ 5 DAYS
DOSAGE: 2.5–5 MG WEEKLY
ACNE: NOT REPORTED
WATER RETENTION: NOT REPORTED
HIGH BLOOD PRESSURE (HBP): POSSIBLE
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: PEPTIDE HUBS
LABORATORY TESTED: VIEW LAB RESULTS
Peptide Hubs Tirzep 5 mg delivers high-purity Tirzepatide for advanced weight management and metabolic enhancement. Each 2 mL vial contains 5 mg of lab-tested Tirzepatide, formulated for consistent research quality and maximum potency.
Tirzep contains Tirzepatide, a dual GIP and GLP-1 receptor agonist. It supports weight loss, improves insulin sensitivity, and helps regulate appetite and blood glucose levels. Tirzepatide has gained attention as a promising option for obesity and type 2 diabetes management [Clinical Study].
Research protocols typically start with low doses (e.g., 2.5–5 mg weekly) and titrate upward depending on tolerance. Subcutaneous injection is the common administration method. Professional medical supervision is strongly recommended when researching Tirzepatide.
For enhanced metabolic benefits, consider stacking with Retatrutide by Peptide Hubs. Explore more advanced research peptides in the Peptide Hubs USA category.
Peptide Hubs is dedicated to supplying lab-tested peptides manufactured with strict quality control, offering researchers access to premium-grade compounds for professional study purposes.
Tirzep is used in research for promoting weight loss, improving insulin sensitivity, regulating blood glucose levels, and supporting overall metabolic health through dual GIP and GLP-1 receptor activation.
Typical research protocols start at 2.5–5 mg weekly administered subcutaneously, with gradual dose escalation depending on tolerance and study goals.
Tirzepatide has shown a favorable safety profile in clinical trials, but side effects like gastrointestinal discomfort and mild hypertension have been reported. Professional supervision is advised.
You can purchase lab-tested Tirzep 5 mg from our Peptide Hubs USA section, featuring premium-quality research peptides.
Please log in to write TIRZEP 5 MG review.
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (20 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: STEALTH LABS USA
LABORATORY TESTED: VIEW LAB RESULTS
SHIPPED WITHOUT LABEL!
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HIGH BLOOD PRESSURE (HBP)): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: KALPA PHARMACEUTICALS
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HIGH BLOOD PRESSURE (HBP)): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS